| |
| |
|
| Insider
Information: |
Allouche Cyril |
| Relationship: |
Principal Accounting O... |
| City: |
Newark |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
6,400 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$21,760 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
6,400 |
|
|
| Total
Value |
$21,760 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Revance Therapeutics, Inc. |
RVNC |
Principal Accounting O... |
2019-03-18 |
6,400 |
2018-06-20 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
14 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2019-03-18 |
4 |
AS |
$15.48 |
$7,709 |
D/D |
(498) |
6,400 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2019-03-15 |
4 |
D |
$15.45 |
$3,893 |
D/D |
(252) |
6,898 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2019-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,150 |
7,150 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2019-01-22 |
4 |
AS |
$17.77 |
$11,106 |
D/D |
(625) |
4,000 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2019-01-22 |
4 |
OE |
$13.35 |
$8,344 |
D/D |
625 |
4,625 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2019-01-03 |
4 |
AS |
$19.48 |
$7,305 |
D/D |
(375) |
4,000 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2018-12-31 |
4 |
A |
$17.11 |
$6,416 |
D/D |
375 |
4,375 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2018-11-20 |
4 |
AS |
$20.66 |
$10,144 |
D/D |
(491) |
4,000 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2018-11-15 |
4 |
D |
$20.99 |
$5,436 |
D/D |
(259) |
4,491 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2018-11-09 |
4 |
AS |
$23.72 |
$51,899 |
D/D |
(2,188) |
4,750 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Accounting Officer |
• – – |
2018-11-09 |
4 |
OE |
$13.35 |
$29,210 |
D/D |
2,188 |
6,938 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Financial Officer |
• – – |
2018-07-06 |
4 |
AS |
$28.35 |
$11,142 |
D/D |
(393) |
4,750 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Financial Officer |
• – – |
2018-06-29 |
4 |
A |
$23.33 |
$9,170 |
D/D |
393 |
5,143 |
0 |
- |
|
| RVNC |
Revance Therapeutics, Inc... |
Principal Financial Officer |
• – – |
2018-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
250 |
4,750 |
0 |
- |
|
14 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
